A Study of XW001 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 3, 2021

Primary Completion Date

June 20, 2022

Study Completion Date

June 20, 2022

Conditions

Respiratory Syncytial Virus Infections

Interventions

DRUG

XW001

Inhaled XW001

DRUG

Placebo

Matched inhaled placebo

Trial Locations (1)

The Third Hospital of Changsha, Changsha

All Listed Sponsors

lead

Hangzhou Sciwind Biosciences Co., Ltd.

INDUSTRY

NCT05642403 - A Study of XW001 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter